What is the Optimal Frequency of Visual Field Testing to Detect Rapid Progression Among Hypertensive Eyes?
Journal
Journal of glaucoma
ISSN: 1536-481X
Titre abrégé: J Glaucoma
Pays: United States
ID NLM: 9300903
Informations de publication
Date de publication:
01 09 2023
01 09 2023
Historique:
received:
21
03
2023
accepted:
12
06
2023
medline:
31
8
2023
pubmed:
21
6
2023
entrez:
21
6
2023
Statut:
ppublish
Résumé
We evaluated 16,351 visual field (VF) tests from Ocular Hypertension Treatment Study (OHTS) database and showed that more frequent testing resulted in a shorter time to detect glaucoma progression, with the best trade-off being the 6-month intervals for high-risk and 12 months for low-risk patients. To investigate the effect of different testing intervals on time to detect visual field progression in eyes with ocular hypertension. A total of 16,351 reliable 30-2 VF tests from 1575 eyes of the OHTS-1 observation arm with a mean (95% CI) follow-up of 4.8 (4.7-4.8) years were analyzed. Computer simulations (n = 10,000 eyes) based on mean deviation values and the residuals of risk groups (according to their baseline 5 y risk of developing primary open angle glaucoma: low, medium, and high risk) were performed to estimate time to detect progression with testing intervals of 4, 6, 12, and 24 months using linear regression. The time to detect VF progression ( P < 5%) at 80% power was calculated based on the mean deviation slope of -0.42 dB/year. We assessed the time to detect a -3 dB loss as an estimate of clinically meaningful perimetric loss. At 80% power, based on the progression of -0.42 dB/year, the best trade-off to detect significant rates of VF change to clinically meaningful perimetric loss in high, medium, and low-risk patients was 6, 6, and 12-month intervals, respectively. Given the importance of not missing the conversion to glaucoma, the frequency of testing used in OHTS (6 mo) was optimal for the detection of progression in high-risk patients. Low-risk patients could potentially be tested every 12 months to optimize resource utilization.
Identifiants
pubmed: 37343189
doi: 10.1097/IJG.0000000000002260
pii: 00061198-990000000-00236
doi:
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
721-724Informations de copyright
Copyright © 2023 Wolters Kluwer Health, Inc. All rights reserved.
Déclaration de conflit d'intérêts
Disclosure: B.M.: Coordenação de Aperfeiçoamento de Pessoal de Nível Superior (CAPES), Brasília, DF, Brazil. C.G.D.M.: Consultant: Belite—San Diego, CA; Reichert—Buffalo, NY; Novartis—East Hanover, NJ; Galimedix Therapeutics Inc.—Kensington, MD; Théa Pharmaceuticals, Inc.—Clemont-Ferrand, France; Carl Zeiss Meditec Inc.—Dublin, CA; Perfuse Therapeutics—San Francisco, CA; Ora Clinical, Inc.—Andover, MA; Recipient: Heidelberg Engineering GmbH—Heidelberg, Germany; Topcon Medical Systems—Oakland, NJ. J.S.P.: Consultant: Allergan, Inc.—Dublin, Ireland. M.O.G.: National Eye Institute, National Institutes of Health. M.A.K.: National Eye Institute, National Institutes of Health. J.M.L.: Consultant: Aerie Pharmaceuticals, Inc.—Pittsburgh, PA; Eyenovia—New York NY; Heidelberg Engineering, GmBH—Heidelberg, Germany; NY:—Laval, Canada; Novartis—East Hanover, NJ; Galimedix Therapeutics Inc.—Kensington, MD; Bausch Healthcare, Inc.—Bridgewater, NJ; Allergan, Inc.—Dublin, Ireland. Financial Support: Heidelberg Engineering, GmBH—Heidelberg, Germany; National Eye Institute—Bethesda, MD; Research to Prevent Blindness, New York, NY. The remaining authors declare no conflict of interest.
Références
Adelson JD, Bourne RRA, Briant PS, et al. Causes of blindness and vision impairment in 2020 and trends over 30 years, and prevalence of avoidable blindness in relation to VISION 2020: the Right to Sight: an analysis for the Global Burden of Disease Study. Lancet Global Health. 2020;9:E144–E160.
Leske MC, Heijl A, Hussein M, et al. Factors for glaucoma progression and the effect of treatment: the early manifest glaucoma trial. Arch Ophthalmol. 2003;121:48–56.
Leske MC, Heijl A, Hyman L, et al. Predictors of long-term progression in the. Early Manifest Glaucoma Trial. 2007;114:1965–1972.
Kass MA, Heuer DK, Higginbotham EJ, et al. The Ocular Hypertension Treatment Study: a randomized trial determines that topical ocular hypotensive medication delays or prevents the onset of primary open-angle glaucoma. Arch Ophthalmol. 2002;120:701–713.
Bron A, Baudouin C, Nordmann JP, et al. Prevalence of intraocular hypertension and glaucoma in a nonselected French population. J Fr Ophtalmol. 2006;29:635–641.
Hashemi H, Khabazkhoob M, Emamian MH, et al. Distribution of intraocular pressure and its determinants in an Iranian adult population. Int J Ophthalmol. 2016;9:1207–1214.
Colton T, Ederer F. The distribution of intraocular pressures in the general population. Surv Ophthalmol. 1980;25:123–129.
Gordon MO, Kass MA. The Ocular Hypertension Treatment Study: design and baseline description of the participants. Arch Ophthalmol. 1999;117:573–583.
Kass MA, Heuer DK, Higginbotham EJ, et al. Assessment of cumulative incidence and severity of primary open-angle glaucoma among participants in the Ocular Hypertension Treatment Study after 20 years of follow-up. JAMA Ophthalmol. 2021;139:1–9.
de Moraes CG, Hood DC, Thenappan A, et al. 24-2 visual fields miss central defects shown on 10-2 tests in glaucoma suspects, ocular hypertensives, and early glaucoma. Ophthalmology. 2017;124:1449–1456.
Keltner JL, Johnson CA, Quigg JM, et al. Confirmation of visual field abnormalities in the Ocular Hypertension Treatment Study. Arch Ophthalmol. 2000;118:1187–1194.
Wu Z, Saunders LJ, Daga FB, et al. Frequency of testing to detect visual field progression derived using a longitudinal cohort of glaucoma patients. Ophthalmology. 2017;124:786–792.
Burr JM, Botello-Pinzon P, Takwoingi Y, et al. Surveillance for ocular hypertension: An evidence synthesis and economic evaluation. Health Technol Assess (Rockv). 2012;16:1–266.
Liebmann JM. Ophthalmology and glaucoma practice in the COVID-19 era. J Glaucoma. 2020;29:407–408.
de Moraes CG, Demirel S, Gardiner SK, et al. Effect of treatment on the rate of visual field change in the ocular hypertension treatment study observation group. Invest Ophthalmol Vis Sci. 2012;53:1704–1709.
Wild JM, Pacey IE, Hancock SA, et al. Between-algorithm, between-individual differences in normal perimetric sensitivity: full threshold, FASTPAC, and SITA. Invest Ophthalmol Vis Sci. 1990;40:1152–1161.
Budenz DL, Rhee P, Feuer WJ, et al. Comparison of glaucomatous visual field defects using standard full threshold and Swedish interactive threshold algorithms. Arch Ophthalmol. 2002;120:1136–1141.
Ocular Hypertension Treatment Study Group European Glaucoma Prevention Study Group. Validated prediction model for the development of primary open-angle glaucoma in individuals with ocular hypertension. Ophthalmology. 2007;114:10–19.e2.
Demirel S, de Moraes CGV, Gardiner SK, et al. The rate of visual field change in the ocular hypertension treatment study. Invest Ophthalmol Vis Sci. 2012;53:224–227.
Gracitelli CPB, Zangwill LM, Diniz-Filho A, et al. Detection of glaucoma progression in individuals of African descent compared with those of European descent. JAMA Ophthalmol. 2018;136:329–335.
Wu Z, Medeiros FA. Comparison of visual field point-wise event-based and global trend-based analysis for detecting glaucomatous progression. Transl Vis Sci Technol. 2018;7:20.
de Moraes CG, Liebmann JM, Levin LA. Detection and measurement of clinically meaningful visual field progression in clinical trials for glaucoma. Prog Retin Eye Res. 2017;56:107–147.
McKean-Cowdin R, Varma R, Wu J, et al. Severity of visual field loss and health-related quality of life. Am J Ophthalmol. 2007;143:1013–1023.
Gordon MO, Torri V, Miglior S, et al. Validated prediction model for the development of primary open-angle glaucoma in individuals with ocular hypertension. Ophthalmology. 2007;114:10–19.
Blumberg DM, de Moraes CG, Liebmann JM, et al. Technology and the glaucoma suspect. Invest Ophthalmol Vis Sci. 2016;57:OCT80–OCT85.